News

While the drugs have grown in popularity among doctors and patients, they are generally too expensive for most people to ...
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications announced today that it ...